Literature DB >> 15481051

Macrophagic response to human mesenchymal stem cell and poly(epsilon-caprolactone) implantation in nonobese diabetic/severe combined immunodeficient mice.

Zhidao Xia1, Hua Ye, Cleo Choong, David J P Ferguson, Nick Platt, Zhanfeng Cui, James T Triffitt.   

Abstract

Nonobese diabetic, severe combined immunodeficient (NOD/SCID) mice are extensively used to assess in vivo potentials for human cellular differentiation, development, and neophysiology. They are not only deficient in T and B cells, but also exhibit macrophage dysfunction and an absence of circulating complement. However, the survival of engrafted human mesenchymal stem cells (hMSCs) is limited and minimal mature bone tissue develops from implanted hMSCs in this model. The aim of the present study was to investigate the response to such implants in NOD/SCID mice. To this end, hMSCs genetically marked with enhanced green fluorescent protein, a biodegradable polymer, poly(epsilon-caprolactone) (PCL), and a bioconstruct incorporating the enhanced green fluorescent protein-labeled hMSCs with PCL after culture together for 3 weeks in vitro, were implanted into NOD/SCID mice and followed for up to 10 weeks. Monocytes/macrophages appeared to be the major invading cell type in all the implants and remained in the materials regardless of whether or not hMSCs were present over the time periods studied. When the hMSCs were implanted without the PCL scaffold, host macrophage invasion was also observed with the majority of hMSCs being eliminated within 2 weeks. Multinuclear giant cells or foreign body giant cells were seen in the cases of PCL implantation. These cells slowly infiltrated into the central core of the materials over a 10-week period of implantation with neutrophils and mast cells also being observed. In conclusion, in NOD/SCID mice, monocytes/macrophages still effectively respond to the implantation of xenografts and biopolymers with functional migration, phagocytosis, adhesion, foreign body recognition and formation of multinuclear giant cells, or foreign body giant cells. Thus, these animals still retain a level of innate immune responsiveness to these implantations and in addition may provoke a physiological environment that is unsuitable for extensive intramembranous ossification by engrafted hMSCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15481051     DOI: 10.1002/jbm.a.30185

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  11 in total

Review 1.  Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

Authors:  Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

2.  Species- and cell type-specific interactions between CD47 and human SIRPalpha.

Authors:  Shyamsundar Subramanian; Ranganath Parthasarathy; Shamik Sen; Eric T Boder; Dennis E Discher
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 3.  Three-dimensional scaffolds for tissue engineering applications: role of porosity and pore size.

Authors:  Qiu Li Loh; Cleo Choong
Journal:  Tissue Eng Part B Rev       Date:  2013-06-25       Impact factor: 6.389

Review 4.  Mesenchymal stem cells: immune evasive, not immune privileged.

Authors:  James A Ankrum; Joon Faii Ong; Jeffrey M Karp
Journal:  Nat Biotechnol       Date:  2014-02-23       Impact factor: 54.908

5.  Growth, differentiation, transplantation and survival of human skeletal myofibers on biodegradable scaffolds.

Authors:  Lieven Thorrez; Janet Shansky; Lin Wang; Loren Fast; Thierry VandenDriessche; Marinee Chuah; David Mooney; Herman Vandenburgh
Journal:  Biomaterials       Date:  2008-01       Impact factor: 12.479

6.  The use of 3-D culture in peptide hydrogel for analysis of discoidin domain receptor 1-collagen interaction.

Authors:  Daizo Yoshida; Akira Teramoto
Journal:  Cell Adh Migr       Date:  2007-04-21       Impact factor: 3.405

7.  Establishment of efficacy and safety assessment of human adipose tissue-derived mesenchymal stem cells (hATMSCs) in a nude rat femoral segmental defect model.

Authors:  Hyung Jun Choi; Jong Min Kim; Euna Kwon; Jeong-Hwan Che; Jae-Il Lee; Seong-Ryul Cho; Sung Keun Kang; Jeong Chan Ra; Byeong-Cheol Kang
Journal:  J Korean Med Sci       Date:  2011-03-28       Impact factor: 2.153

8.  Influence of osteogenic stimulation and VEGF treatment on in vivo bone formation in hMSC-seeded cancellous bone scaffolds.

Authors:  Ulrich Lenze; Florian Pohlig; Sebastian Seitz; Christina Ern; Stefan Milz; Denitsa Docheva; Matthias Schieker
Journal:  BMC Musculoskelet Disord       Date:  2014-10-16       Impact factor: 2.362

9.  A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies.

Authors:  N Lee; A J Smolarz; S Olson; O David; J Reiser; R Kutner; N C Daw; D J Prockop; E M Horwitz; C A Gregory
Journal:  Br J Cancer       Date:  2007-11-06       Impact factor: 7.640

10.  Immunosuppressant Drugs Mitigate Immune Responses Generated by Human Mesenchymal Stem Cells Transplanted into the Mouse Parenchyma.

Authors:  Jung Won Hwang; Su Hyeon Myeong; Na-Hee Lee; Hyeongseop Kim; Hyo Jin Son; Jong Wook Chang; Na Kyung Lee; Duk L Na
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.